← Browse by Condition
Medical Condition

immune checkpoint inhibitor

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for immune checkpoint inhibitor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — immune checkpoint inhibitor Clinical Trials

How many clinical trials are currently recruiting for immune checkpoint inhibitor?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for immune checkpoint inhibitor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for immune checkpoint inhibitor?
immune checkpoint inhibitor research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a immune checkpoint inhibitor clinical trial?
Eligibility criteria for immune checkpoint inhibitor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Institut Mutualiste Montsouris 1 trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 1 trial
Xinqiao Hospital of Chongqing 1 trial
Tianjin Medical University Cancer Institute and Hospital 1 trial
Samsung Medical Center 1 trial

Recruiting Clinical Trials

NCT05799898
Recruiting
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
Enrollment
200 pts
Location
France
Sponsor
Institut Mutualiste Montsouris
View Trial →
NCT06197581
Recruiting
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Enrollment
148 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT05754203
Recruiting
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
Enrollment
40 pts
Location
China
Sponsor
Xinqiao Hospital of Chongqing
View Trial →
NCT07058948 Phase 2
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Tianjin Medical University Can...
View Trial →
NCT06259162
Recruiting
LAG3 Expression in Triple Negative Breast Cancer
Enrollment
128 pts
Location
South Korea
Sponsor
Samsung Medical Center
View Trial →

Related Conditions

lung cancer (2) radiotherapy (2) cancer (1) cardiovascular complication (1) immune related adverse event (1) breast cancer familial male (1) radiotherapy complications (1) chemotherapeutic toxicity (1) cdk4 6 inhibitor (1) trastuzumab (1) pertuzumab (1) parp inhibitor (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology